Mumbai, May 21 (Udaipur Kiran): Strides Pharma Science is currently trading at Rs. 1163.60, up by 21.55 points or 1.89% from its previous closing of Rs. 1142.05 on the BSE.
The scrip opened at Rs. 1143.70 and has touched a high and low of Rs. 1171.90 and Rs. 1130.70 respectively. So far 5361 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 1231.45 on 12-May-2026 and a 52 week low of Rs. 681.05 on 21-May-2025.
Last one week high and low of the scrip stood at Rs. 1,231.45 and Rs. 986.95 respectively. The current market cap of the company is Rs. 10797.11 crore.
The promoters holding in the company stood at 27.91%, while Institutions and Non-Institutions held 43.14% and 28.95% respectively.
Strides Pharma Science’s flagship facility in Bangalore has received Form 483 with five observations from United States Food and Drug Administration (USFDA). The USFDA had conducted a routine current Good Manufacturing Practices (cGMP) inspection at the facility during the period from May 12, 2026 to May 20, 2026.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.